On the contrary, patients with SMM in cluster 2 showed a significant increase in the ITIM-bearing inhibitory receptor TIGIT (27, 28) which is consistent with our previous findings demonstrating that TIGIT blockade can be a useful therapeutic strategy in patients with SMM and active MM with Nectin-2 expressing PC (29). The gene discussed is NECTIN2; the disease is Miyoshi myopathy.